Fluidigm Corporation FLDM operates as a biotech tools company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on FLDM’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Fluidigm could be a solid choice for investors.
Current Quarter Estimates for FLDM
In the past 30 days, we have seen no estimate moving in either direction for Fluidigm. However, the trend has been pretty favorable, with estimates narrowing from a loss of 49 cents a share 30 days ago, to a loss of 44 cents today.
Current Year Estimates for FLDM
Meanwhile, Fluidigm’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $2.12 per share 30 days ago to a loss of $1.87 today.
Bottom Line
The stock has also started to move higher lately, adding 43.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment